Faes Farma recorded a net profit of 30.4 million euros in the first quarter of this year, which represents an increase of 10% compared to the same period in 2023, as reported by the company in a press release this Friday.

The group earned 139.4 million euros between January and March 2024, 7% more, while the gross operating result (Ebitda) stood at 41 million euros, 10% more.

The company has attributed the growth in income recorded during the first three months of this year to the “good performance” of the business in Spain, with more than 59 million euros after a growth of 9%.

In addition, international markets, which represent almost 58% of the company’s business, also represent a boost for the group, after growing 6%, to 80.4 million euros.

Faes Farma expects to close this year with an increase in revenue of between 6% and 8% and in Ebitda between 3% and 5%, driven by double-digit growth in the regions of Latin America, the Middle East and Africa and in the licenses for calcifediol and mesalazine.

Likewise, the company plans for this year a stronger increase in expenses related to activity in research, production, commercial work and salary inflation.